Research
Hormonal
Semaglutide 2.4 mg administered weekly results in a mean weight loss of 14.9% over 68 weeks, significantly outperforming placebo.
Semaglutide 2.4 mg, taken as a weekly injection, is a highly effective treatment for obesity, leading to an average 14.9% weight loss over 68 weeks. It works by mimicking the GLP-1 hormone to increase satiety and reduce appetite. Common side effects include gastrointestinal issues like nausea and diarrhea.
StrongSupportsHIGH confidence
In clinical trials, semaglutide 2.4 mg administered weekly resulted in a mean weight loss of 14.9% over 68 weeks, compared to 2.4% with placebo, with 86% of participants achieving at least 5% weight loss
Why this rating
Based on clinical trials cited in the text.
Source
The Growing Obesity Epidemic: Integrating Lifestyle, Pharmacological, and Surgical Interventions for Effective Management
Jan Siwiec et al. · Journal of Education Health and Sport · 2025
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →